Has Vinni Juneja, MD received payments from drug or device companies?

Yes. Drug and device makers reported $769,708 in general payments to Vinni Juneja, MD across 1,062 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vinni Juneja, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vinni Juneja, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vinni Juneja, MD

Hematology & Oncology · Alexandria, VANPI 1639223522

Payments from drug & device makers

$769,708in general payments, 2019–2025

Across 1,062 payments — averaging $724.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Janssen Research & Development, LLC$300K
AbbVie$211K
Daiichi Sankyo Inc.$108K
AstraZeneca$78K
E.r. Squibb & Sons, L.L.C.$24K
G1 Therapeutics, Inc.$16K
plus $32K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Janssen Research & Development, LLC	56	$300,060
AbbVie	35	$211,274
Daiichi Sankyo Inc.	83	$107,930
AstraZeneca(2 entities)	53	$78,317
E.r. Squibb & Sons, L.L.C.	41	$23,890
G1 Therapeutics, Inc.	10	$15,795
Bristol Myers Squibb	33	$6,047
Seagen Inc.	30	$5,320
Pfizer	78	$2,884
Johnson & Johnson(2 entities)	52	$2,723
Novartis	72	$2,297
Takeda Pharmaceuticals U.S.A., Inc.	14	$1,798
Merck	48	$950
Amgen(2 entities)	40	$684
Eisai Inc.	33	$647
Incyte Corporation	23	$521
GSK	19	$514
Sanofi	18	$447
AVEO Pharmaceuticals, Inc.	13	$391
Genentech USA, Inc.	18	$380
Gilead(2 entities)	15	$347
Pharmaessentia USA Corporation	13	$334
Lilly USA, LLC	14	$317
Dendreon Pharmaceuticals LLC	10	$289
Regeneron Healthcare Solutions, Inc.	11	$284
Astellas Pharma US Inc	10	$276
Array Biopharma Inc	12	$269
Bayer	11	$262
Rigel Pharmaceuticals, Inc.	12	$259
Puma Biotechnology, Inc.	13	$253
Beigene USA, Inc.	8	$252
Taiho Oncology, Inc.	10	$241
Boehringer Ingelheim	9	$226
Pharmacyclics LLC, An Abbvie Company	9	$200
Exelixis Inc.	8	$188
Tersera Therapeutics LLC	6	$187
Global Blood Therapeutics, Inc.	8	$181
Sobi, Inc	8	$165
Mirati Therapeutics, Inc.	5	$163
ADC Therapeutics America, Inc.	6	$147
Pharmacosmos Therapeutics Inc.	6	$133
Agios Pharmaceuticals, Inc.	5	$114
Morphosys, US Inc.	5	$111
Ipsen Biopharmaceuticals, Inc	5	$110
EMD Serono, Inc.	4	$92
Secura Bio, Inc.	2	$81
Tactile Systems Technology Inc	5	$75
Adaptive Biotechnologies Corporation	3	$74
Servier Pharmaceuticals LLC	4	$69
Beone Medicines USA, Inc.	3	$69
Genmab U.S., Inc.	2	$69
EUSA Pharma (US) LLC	3	$64
Spectrum Pharmaceuticals Inc.	3	$58
Karyopharm Therapeutics Inc.	3	$55
Immunogen, Inc.	2	$54
Acrotech Biopharma Inc.	3	$53
Alnylam Pharmaceuticals Inc.	4	$51
Clovis Oncology, Inc.	3	$50
Sumitomo Pharma America, Inc.	2	$49
Myriad Genetic Laboratories, Inc.	3	$46

How this compares

$769,708 in reported general payments places this provider in the 85th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia →

Medicare billing

Part B allowed, 2024

$4,146,967

Medicare patients

699

Services billed

247,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Alexandria

Craig PortellCharlottesville$12.9M
Amanda Gillespie-TwardyRoanoke$12.2M
Sekwon JangFairfax$11.8M
Mark FlemingHampton$10M
Mark KochenderferRoanoke$8.6M
Mitul GandhiManassas$6.9M
Michael DansoNorfolk$6.9M
Jerome GoldschmidtChristiansburg$6.5M
William IrvinMidlothian$4.3M
Lakshminarayanan NandagopalFredericksburg$3.9M

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →